http://www.cryocath.com Toronto Stock Exchange Symbol: CYT
MONTREAL, July 2 /PRNewswire-FirstCall/ - CryoCath Technologies Inc. (TSX: CYT), the global leader in cryotherapy products to treat cardiac arrhythmias, today announced the appointment of Frank Vandeputte as Vice President, Europe. Based in CryoCath's new European headquarters in Leiden, The Netherlands, Mr. Vandeputte will be responsible for leading the European business operation. This includes the development and implementation of strategic and operational business plans, with the objective of driving ongoing rapid sales growth of the Company's innovative products in the European market.
Mr. Vandeputte joins CryoCath with more than 20 years of experience in the medical device industry. Most recently, he served as Area Vice President Benelux and Nordic for the Sorin Group, based in Brussels. Prior to that he was Vice President International Marketing with the Sorin Group. Prior to Sorin, he held senior management positions with leading medical device companies, including Baxter International Inc, Becton Dickinson and Guidant Corporation. With Guidant, he has been providing leadership to their European Cardiac Resynchronisation Therapy, Endovascular and Cardiac Surgery business, and served as Country Manager for Germany as well.
"With his proven leadership and medical device industry successes,
Frank will be an asset to our European commercial operations. He, and his
successful European leadership team, will spearhead the ongoing rapid
growth of Arctic Front in Europe," said Jan Keltjens, CryoCath President
and CEO. "Additionally, we have now opened our European headquarters in
Leiden, the Netherlands. This will allow us to better serve the needs of
our expanding customer base in Europe. By establishing a strong European
presence and enhancing our management team, we are continuing to execute on
our strategy of becoming
|SOURCE CryoCath Technologies Inc.|
Copyright©2008 PR Newswire.
All rights reserved